Investment

source: Journal de Montreal

author: AFP Monday, October 12, 2020

translation: GoogleTranslate/doxa-louise

AstraZeneca: US invests in COVID-19 treatment

The US government is investing nearly half a billion dollars in the development and large-scale distribution of a treatment for COVID-19 from the British laboratory AstraZeneca, in late clinical trials, the giant pharmaceutical company in a statement Monday. 

With an investment of $ 486 million, the US government will contribute to the development and distribution of 100,000 doses by the end of 2020 and may acquire a million more in 2021, he says.

"The AZD7442 antibody combination is advancing rapidly in phase 3 trials", adds the group.

Two trials "in the United States and elsewhere" will "enroll 6,000 adults for the prevention of COVID-19 and additional trials on about 4,000 adults will focus on the treatment of contaminations" by the new coronavirus, t is claimed .

The pharmaceutical group, which is developing in parallel with the University of Oxford a "vaccine candidate", considered one of the most promising, announced at the end of August that it had launched phase 1 trials on its drug AZD7442, already funded to the tune of $ 25 million by the US government.

The drug AZD7442 is a combination of two long-lasting antibodies derived from convalescent COVID-19 patients, discovered by the US Medical Center at Vanderbilt University and licensed by AstraZeneca in June.

                                                            *     *     *